Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer-Reference-Cited by-同舟云学术

Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer

Published:2017-12 Issue:6 Volume:15 Page:e1047-e1053
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Buchler Tomas^ORCID,Poprach Alexandr,Bortlicek Zbynek,Lakomy Radek,Chloupková Renata,Vyzula Rostislav,Zemanova Milada,Kopeckova Katerina,Svoboda Marek,Slaby Ondrej,Kiss Igor,Studentova Hana,Hornova Jana,Fiala Ondrej,Kopecky Jindrich,Finek Jindrich,Dusek Ladislav,Melichar Bohuslav

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference23 articles.

1. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial;Rini;Lancet,2011

2. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial;Rini;J Clin Oncol,2014

3. Pazopanib versus sunitinib in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2013

4. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial;Sternberg;J Clin Oncol,2010

5. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma;Rini;Ann Oncol,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy;Targeted Oncology;2024-02-03

2. Patient-derived organoids in translational oncology and drug screening;Cancer Letters;2023-05

3. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma;Expert Review of Anticancer Therapy;2021-04-02

4. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma;Future Oncology;2021-01

5. Mammalian SIRT4 is a tumor suppressor of clear cell renal cell carcinoma by inhibiting cancer proliferation, migration and invasion;Cancer Biomarkers;2020-11-20